Which medication beginning with the letter 'A' is appropriate for controlling tachycardia, tremor, and anxiety in Graves disease, and what is the recommended initial dose?

Atenolol for Symptomatic Control in Graves' Disease

Atenolol is the appropriate medication starting with "A" for controlling tachycardia, tremor, and anxiety in Graves' disease, with a typical starting dose of 50-100 mg daily, titrated up to 200 mg daily as needed for symptom control.

Mechanism and Rationale

Beta-adrenergic blockade addresses the hyperadrenergic symptoms of Graves' disease by:

• Reducing heart rate by approximately 25-30 beats per minute 1, 2
• Controlling tremor, anxiety, and emotional lability 1
• Improving muscle weakness and exercise intolerance 1

Atenolol specifically offers the advantage of once-daily dosing due to its long-acting formulation 3, which improves adherence compared to shorter-acting agents requiring multiple daily doses.

Dosing Strategy

Initial Approach

• Start with 50-100 mg once daily for most patients
• Titrate up to 200 mg daily based on symptom response 2
• Target: resting heart rate below 90 bpm 1

Special Populations Requiring Beta-Blockade

Beta-blockers are mandatory in:

• Elderly patients with symptomatic thyrotoxicosis 1
• Any patient with resting heart rate >90 bpm 1
• Patients with coexistent cardiovascular disease 1
• Children with heart rates >100 bpm 1

All symptomatic patients should be considered for beta-blockade 1, as this provides rapid relief while awaiting definitive treatment effects from antithyroid drugs, radioiodine, or surgery.

Clinical Context

Role in Treatment Algorithm

1. Immediate symptomatic control: Beta-blockers work within hours to days
2. Bridge therapy: Continue while antithyroid drugs (methimazole) take 4-8 weeks to achieve euthyroid status 1
3. Adjunct to definitive treatment: Use alongside radioiodine or as preoperative preparation 4, 3

Cardioselective Advantage

Atenolol's beta-1 selectivity makes it preferable in patients with:

• Mild obstructive airway disease 1
• Reactive airway disease (with careful monitoring) 1

Important caveat: At higher doses, beta-1 selectivity diminishes, so atenolol remains contraindicated in active bronchospastic asthma 1.

Practical Considerations

When Beta-Blockers Are Contraindicated

If atenolol cannot be used:

• Calcium channel blockers (verapamil or diltiazem) provide alternative rate control 1
• Administer orally, not intravenously, for this indication 1

Monitoring

• Assess heart rate and blood pressure at each visit
• Watch for excessive bradycardia or hypotension requiring dose reduction
• In patients with cardiac history, monitor for signs of heart failure (rare but possible) 1

Duration of Therapy

Continue beta-blockade until:

• Euthyroid status achieved with antithyroid drugs (typically 4-8 weeks) 1
• Post-radioiodine when thyroid hormone levels normalize
• Post-thyroidectomy recovery complete

Common Pitfalls to Avoid

1. Underdosing: Don't hesitate to use up to 200 mg daily if symptoms persist 2
2. Abrupt discontinuation: Taper gradually once euthyroid to avoid rebound tachycardia
3. Using as monotherapy: Beta-blockers only control symptoms; they don't treat the underlying hyperthyroidism—always combine with definitive therapy 5
4. Overlooking drug interactions: When used with methimazole, monitor for rare cardiac conduction abnormalities 6

The combination of atenolol for immediate symptom relief plus methimazole for definitive control represents the standard first-line approach for most patients with Graves' disease 1, 4.